La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
73 hedge funds and large institutions have $256M invested in La Jolla Pharmaceutical Company in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.
191% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $1.22M
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4% more funds holding
Funds holding: 70 → 73 (+3)
24% less capital invested
Capital invested by funds: $335M → $256M (-$79.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$11.4M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$2.13M |
| 3 |
BC
Broadfin Capital
New York
|
+$2.08M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.69M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$24.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$2.54M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$616K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$559K |
| 5 |
Millennium Management
New York
|
-$464K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Goldman Sachs
New York
| – | -$329K | -15,743 | Closed |
|
77
Squarepoint
New York
| – | -$303K | -14,500 | Closed |
|
78
Balyasny Asset Management
Chicago,
Illinois
| – | -$264K | -12,630 | Closed |
|
79
Walleye Trading
New York
| – | -$2K | -100 | Closed |
|
80
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$18 | -1 | -3% |
|
LJPC Hedge Fund Activity: Q2 2016 in Review
73 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2016, worth a combined $256M — down 24% from $335M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LJPC positions and 7 closed out — a net gain of 3 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $11.4M. The largest seller was Visium Asset Management, exiting entirely with an estimated $24.8M sold.
- 73 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2016, up from 70 in Q1 2016.
- Funds reported $256M of La Jolla Pharmaceutical Company stock for Q2 2016, down 24% quarter-over-quarter.
- 10 funds opened new La Jolla Pharmaceutical Company positions in Q2 2016 and 7 closed out, a net change of +3 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2016 was Perceptive Advisors, an estimated $11.4M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2016 was Visium Asset Management, an estimated $24.8M sold.
Based on aggregated 13F filings for Q2 2016.